佛慈制药：第三季度归母净利润797.78万元，同比增加167.92%

Core Insights - The company reported a revenue of 195 million yuan for Q3 2025, representing a year-on-year decline of 7.14% [1] - The net profit attributable to shareholders was 7.9778 million yuan, showing a significant increase of 167.92% year-on-year [1] - Basic earnings per share (EPS) for Q3 2025 stood at 0.0156 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 624 million yuan, which is a year-on-year decrease of 11.92% [1] - The net profit attributable to shareholders for the first three quarters was 38.0824 million yuan, reflecting a slight decline of 2.54% year-on-year [1] - Basic earnings per share (EPS) for the first three quarters was reported at 0.0746 yuan [1]